SCHEMBL6487907

SCHEMBL6487907

CCc1ccc(-c2ccc(C(F)(F)F)cc2)c(C(=O)O)c1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PSEN1 P49768 1/20 0.56
PSEN2 P49810 1/20 0.56
APH1B Q8WW43 1/20 0.56
NCSTN Q92542 1/20 0.56
APH1A Q96BI3 1/20 0.56
PSENEN Q9NZ42 1/20 0.56
CYP2C8 P10632 1/20 0.52
FOLH1 Q04609 2/20 0.50
APP P05067 1/20 0.48
PPARA Q07869 1/20 0.46
AKR1C3 P42330 2/20 0.45
AKR1C2 P52895 2/20 0.45
TACR1 P25103 1/20 0.44
HSD17B10 Q99714 1/20 0.44
RXRA P19793 3/20 0.44
RXRB P28702 3/20 0.44
RXRG P48443 2/20 0.44
BACE1 P56817 1/20 0.44
ACLY P53396 1/20 0.44
ALOX5AP P20292 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3168574 0.84 METAP2 (0.54) FOLH1PPARAHSD17B10SMN1; SMN2PTPN11
SCHEMBL6491569 0.82 FOLH1 (0.55) FOLH1AKR1C2HSD17B10RXRARXRB
SCHEMBL3737187 0.82 FOLH1 (0.71) FOLH1HSD17B10SMN1; SMN2PTPN11RAB9A
SCHEMBL6498615 0.81 FOLH1 (0.54) FOLH1HSD17B10SMN1; SMN2PTPN11RAB9A
SCHEMBL6491531 0.81 CYP2C8 (0.56) PSEN1PSEN2APH1BNCSTNAPH1A
SCHEMBL6488790 0.80 AKR1C3 (0.58) PSEN1PSEN2APH1BNCSTNAPH1A
SCHEMBL6501365 0.80 PTPN11 (0.54) PSEN1PSEN2APH1BNCSTNAPH1A
SCHEMBL3909846 0.79 CYP2C8 (0.57) PSEN1PSEN2APH1BNCSTNAPH1A
SCHEMBL6492505 0.79 CYP2C8 (0.57) PSEN1PSEN2APH1BNCSTNAPH1A
SCHEMBL6500539 0.78 AKR1C3 (0.61) PSEN1PSEN2APH1BNCSTNAPH1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050038035-A1 Heterocyclic amide compounds as apolipoprotein b inhibitors DAISO CO., LTD. (JP) 2005-02-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050038035-A1 Heterocyclic amide compounds as apolipoprotein b inhibitors APOB, APOL1, CTRB2 PSEN1 301/4885PSEN2 311/4885APH1B 36/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.